You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Studies show that pain and anxiety from shocks can lead to decreased quality of life and participation in normal activities.1 Furthermore, these shocks can lead to unnecessary hospital admissions,2 which can result in increased costs and resource usage.
SmartShock™ 2.0 Technology reduces the incidence of inappropriate shocks while maintaining sensitivity.3,4 In fact, 98.5% of dual chamber and triple chamber patients, and 97.5% of single chamber patients were free from inappropriate shocks at one year post-implant.2
Graph is a summary of the PainFree SST study.
Wathen MS, et al. Circulation. 2004;110:2591-2596.
Volosin KJ, et al. J Cardiovasc Electrophysiol. 2011;22:280-289.
Protecta Clinical Study, Medtronic data on file.